Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases.

 

The company was founded in June 2009. Orphazyme is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen. Their pioneering work on the cytoprotective properties of human heat shock proteins provides a novel and paradigm-changing approach to developing medicines for the treatment lysosomal storage diseases. 

 

Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.